1. Volume 142, Issue 6, Pages 1356-1359 (May 2012)
Is There a Role for Ribavirin in the Era of Hepatitis C Virus Direct-Acting Antivirals? 
Jordan J. Feld 
Gastroenterology 
Volume 142, Issue 6, Pages (May 2012)
DOI: /j.gastro
Copyright © 2012 AGA Institute Terms and Conditions

2. Figure 1
Early breakthrough and/or relapse with exclusion of ribavirin. A schematic of HCV RNA decline is shown with telaprevir-containing regimens in the PROVE 2 trial. Initial viral decline was similar with or without ribavirin (green); however, after 2 weeks, viral breakthrough with telaprevir-resistant variants emerged (pink) in patients treated with telaprevir and peginterferon without ribavirin (blue line). For those who became undetectable during therapy, the presence of ribavirin also reduced the risk of relapse after treatment was stopped.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions

3. Gastroenterology 2012 142, 1356-1359DOI: (10. 1053/j. gastro. 2011. 12
Copyright © 2012 AGA Institute Terms and Conditions